Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment

British Journal of Dermatology

Volumn 156, Issue 6, 2007, Pages 1204-1213

  Meier, F ^a   Busch, S ^a   Lasithiotakis, K ^a   Kulms, D ^b   Garbe, C ^a   Maczey, E ^a   Herlyn, M ^c   Schittek, B ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF STUTTGART   (Germany)

^c WISTAR INSTITUTE   (United States)

Author keywords

AKT; ERK; MAPK; Melanoma; PI3K; Signalling

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SORAFENIB; WORTMANNIN;

APOPTOSIS; ARTICLE; CANCER INVASION; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; SKIN CULTURE;

ANDROSTADIENES; APOPTOSIS; BENZENESULFONATES; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DIMETHYL SULFOXIDE; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; SIGNAL TRANSDUCTION;

EID: 34447104362     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.07821.x     Document Type: Article

References (29)

1. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002 417: 949 54.
2. Meier F, Schittek B, Busch S et al. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci 2005 10: 2986 3001.
3. Li G, Kalabis J, Xu X et al. Reciprocal regulation of MelCAM and AKT in human melanoma. Oncogene 2003 22: 6891 9.
4. Stupack DG, Cheresh DA. Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci 2002 115: 3729 38.
5. Woods D, Cherwinski H, Venetsanakos E et al. Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway. Mol Cell Biol 2001 21: 3192 205.
6. Karasarides M, Chiloeches A, Hayward R et al. B-RAF is a therapeutic target in melanoma. Oncogene 2004 23: 6292 8.
7. Ahmad T, Marais R, Pyle L et al. BAY 43-9006 in patients with advanced melanoma: the Royal Marsden experience. J Clin Oncol 2004 22: 7506.
8. Pittelkow MR, Scott RE. New techniques for the in vitro culture of human skin keratinocytes and perspectives on their use for grafting of patients with extensive burns. Mayo Clin Proc 1986 61: 771 7.
9. Meier F, Nesbit M, Hsu MY et al. Human melanoma progression in skin reconstructs: biological significance of bFGF. Am J Pathol 2000 156: 193 200.
10. Zouboulis CC, Garbe C, Krasagakis K et al. A fluorometric rapid microassay to identify anti-proliferative compounds for human melanoma cells in vitro. Melanoma Res 1991 1: 91 5.
11. Bedogni B, O'Neill MS, Welford SM et al. Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice. Cancer Res 2004 64: 2552 60.
12. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004 64: 7099 109.
13. Solit DB, Garraway LA, Pratilas CA et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006 439: 358 62.
14. Meyer P, Klaes R, Schmitt C et al. Exclusion of BRAFV599E as a melanoma susceptibility mutation. Int J Cancer 2003 106: 78 80.
15. Satyamoorthy K, Li G, Gerrero MR et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003 63: 756 9.
16. Tsurutani J, West KA, Sayyah J et al. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res 2005 65: 8423 32.
17. Krystal GW, Sulanke G, Litz J. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther 2002 1: 913 22.
18. Stassi G, Garofalo M, Zerilli M et al. PED mediates AKT-dependent chemoresistance in human breast cancer cells. Cancer Res 2005 65: 6668 75.
19. Choi EK, Park HJ, Ma JS et al. LY294002 inhibits monocyte chemoattractant protein-1 expression through a phosphatidylinositol 3-kinase-independent mechanism. FEBS Lett 2004 559: 141 4.
20. Tolloczko B, Turkewitsch P, Al-Chalabi M, Martin JG. LY-294002 [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] affects calcium signaling in airway smooth muscle cells independently of phosphoinositide 3-kinase inhibition. J Pharmacol Exp Ther 2004 311: 787 93.
21. Stewart AL, Mhashilkar AM, Yang XH et al. PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells. Mol Med 2002 8: 451 61.
22. Reddy KB, Nabha SM, Atanaskova N. Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 2003 22: 395 403.
23. Smalley KS. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 2003 104: 527 32.
24. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001 98: 10983 5.
25. Hofmann UB, Westphal JR, Waas ET et al. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression. Br J Cancer 1999 81: 774 82.
26. Kurschat P, Zigrino P, Nischt R et al. Tissue inhibitor of matrix metalloproteinase-2 regulates matrix metalloproteinase-2 activation by modulation of membrane-type 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines. J Biol Chem 1999 274: 21056 62.
27. Park BK, Zeng X, Glazer RI. Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells. Cancer Res 2001 61: 7647 53.
28. Welch DR, Sakamaki T, Pioquinto R et al. Transfection of constitutively active mitogen-activated protein/extracellular signal-regulated kinase kinase confers tumorigenic and metastatic potentials to NIH3T3 cells. Cancer Res 2000 60: 1552 6.
29. Smalley KS, Haass NK, Brafford PA et al. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006 5: 1136 44.